StockNews.AI
DBVT
StockNews.AI
21 days

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

1. DBV Technologies filed its 2025 Half-Year Report with AMF. 2. DBV focuses on treating food allergies with the VIASKIN® patch. 3. The company conducts clinical trials on peanut allergies in toddlers. 4. DBV's technology offers non-invasive allergy treatment through EPIT. 5. The report is accessible via the company's website and AMF.

4m saved
Insight
Article

FAQ

Why Bullish?

The filing of the Half-Year Report enhances investor transparency and may boost confidence, similar to positive responses seen after other biotech reporting periods.

How important is it?

The report lays out the company's progress and strategy, which may influence investor sentiment positively, especially as it outlines ongoing trials significant for DBVT's valuation.

Why Short Term?

The immediate availability of results from ongoing clinical trials could yield swift reactions in price, often evident in biotech stocks after significant news.

Related Companies

DBVVRTXREGN
Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2025, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”). The 2025 Half-Year Report can be consulted or downloaded from the Company’s website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only. It is also available free of charge upon request: - by mail : DBV Technologies – 107 avenue de la République 92320 Châtillon, France ; - by email: investors@dbv-technologies.com. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309). For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Technologieskatie.matthews@dbv-technologies.com Media ContactBrett WhelanDBV Technologiesbrett.whelan@dbv-technologies.com PDF Version

Related News